A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Research Site, Roma

Research Site, Badalona

Research Site, Bangkok

Research Site, Long Island City

Research Site, Athens

Research Site, Suwon

Research Site, Milan

Research Site, Baltimore

Research Site, Majadahonda

Research Site, Haifa

Research Site, Pessac

Research Site, Bassano del Grappa

Research Site, Seville

Research Site, Cleveland

Research Site, Florence

Research Site, Thessaloniki

Research Site, Lille

Research Site, Chicago

Research Site, Kansas City

Research Site, Pierre-Bénite

Research Site, Paris

Research Site, Avellino

Research Site, Kota Kinabalu

Research Site, Reggio Calabria

Research Site, Los Angeles

Research Site, Jerusalem

Research Site, Kuching

Research Site, Miri

Research Site, Dallas

Research Site, Porto Alegre

Research Site, Rio de Janeiro

Research Site, Toronto

Research Site, Brno

Research Site, Bunkyō City

Research Site, Kyoto

Research Site, Osaka

Research Site, Shibuya-ku

Research Site, Tsukuba

Research Site, Gdansk

Research Site, Seoul

Research Site, Seoul

Research Site, Barcelona

Research Site, Airdrie

Research Site, Leeds

Research Site, London